1 |
吴国明,钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
|
2 |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
|
3 |
Dlamini SB, Sartorius B, Ginindza TG. Pre- and post-intervention survey on lung cancer awareness among adults in selected communities in KwaZulu-Natal, South Africa: A quasi-experimental study[J]. J Public Health Africa, 2023, 14(1): 2131.
|
4 |
Alexander M, Kim SY, Cheng H. Update 2020: Management of Non-Small Cell Lung Cancer[J]. Lung, 2020, 198(6): 897-907.
|
5 |
Miyazawa T, Marushima H, Saji H, et al. PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes[J]. Ann Thorac Cardiovasc Surg, 2019, 25(1): 1-9.
|
6 |
Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics[J]. J Hematol Oncol, 2019, 12(1): 92.
|
7 |
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nature Reviews Cancer, 2012, 12(4): 252-264.
|
8 |
Aguilar EJ, Ricciuti B, Gainor JF, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression[J]. Ann Oncol, 2019, 30(10): 1653-1659.
|
9 |
Lee DJ, Lee HJ, Jr., Farmer JR, et al. Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors[J]. Current Cardiol Reports, 2021, 23(8): 98.
|
10 |
Kitagawa S, Hakozaki T, Kitadai R, et al. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review[J]. Thorac Cancer, 2020, 11(7): 1927-1933.
|
11 |
Polański J, Chabowski M, Swiᶏtoniowska-Lonc N, et al. Relationship between nutritional status and clinical outcome in patients treated for lung cancer[J]. Nutrients, 2021, 13(10): 3332.
|
12 |
曾 燕,东 燕,刘军妮. NRS-2002评分与PG-SGA评分法在老年消化道肿瘤患者中的应用[J]. 齐鲁护理杂志,2021, 27(19): 76-79.
|
13 |
王会杰,孙珍贵,赵文英,等. S100A10可促进肺腺癌细胞的增殖和侵袭:基于激活Akt-mTOR信号通路[J]. 南方医科大学学报,2023, 43(5): 733-740.
|
14 |
Tan D, Wang S, Zhang P, et al. LncRNA SNHG12 decreases non-small cell lung cancer cell sensitivity to cisplatin by repressing miR-525-5p and promoting XIAP[J]. Ann Clin laborat Sci, 2023, 53(1): 64-75.
|
15 |
Song M, Zhang Q, Song C, et al. The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer[J]. J Cachexia Sarcopenia Muscle, 2022, 13(5): 2504-2514.
|
16 |
张 正. 影响胃癌术后化疗患者营养状态的危险因素分析[J]. 吉林医学,2022, 43(7): 2008-2010.
|
17 |
Grisold W, Löscher W, Grisold A. Neurological complications of systemic tumor therapy[J]. Wien Med Wochenschr, 2019, 169(1-2): 33-40.
|
18 |
Moustou AE, Matekovits A, Dessinioti C, et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review[J]. J Am Acad Dermatol, 2009, 61(3): 486-504.
|
19 |
Serra López-Matencio JM, Gómez Garcia De Soria V, Gómez M, et al. Monitoring and safety of CAR-T therapy in clinical practice[J]. Expert Opin Drug Saf, 2022, 21(3): 363-371.
|
20 |
Bustillos H, Indorf A, Alwan L, et al. Xerostomia: an immunotherapy-related adverse effect in cancer patients[J]. Support Care Cancer, 2022, 30(2): 1681-1687.
|
21 |
Peterson SJ, Mozer M. Differentiating sarcopenia and cachexia among patients with cancer[J]. Nutr Clin Pract, 2017, 32(1): 30-39.
|
22 |
Polański J, Jankowska-Polańska B, Uchmanowicz I, et al. Malnutrition and quality of life in patients with non-small-cell lung cancer [J]. Adv Exp Med Biol, 2017, 1021: 15-26.
|
23 |
Shiroyama T, Nagatomo I, Koyama S, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study[J]. Scientific Reports, 2019, 9(1): 2447.
|
24 |
Bacha S, Mejdoub El Fehri S, Habibech S, et al. Impact of malnutrition in advanced non-small cell lung cancer[J]. Tunis Med, 2018, 96(1): 59-63.
|
25 |
岳 岚,李 珍,李锡清,等. 衰弱及血常规指标对肿瘤病人发生免疫相关不良反应的预测价值研究[J]. 全科护理,2022, 20(9): 1153-1156.
|
26 |
Niemeläinen S, Huhtala H, Andersen J, et al. The Clinical Frailty Scale is a useful tool for predicting postoperative complications following elective colon cancer surgery at the age of 80 years and above: A prospective, multicentre observational study[J]. Colorectal Dis, 2021, 23(7): 1824-1836.
|
27 |
Guo J, Yang Q, Jiang Q, et al. Integrating baseline nutritional and inflammatory parameters with post-treatment EBV DNA level to predict outcomes of patients with De Novo metastatic nasopharyngeal carcinoma receiving chemotherapy combination PD-1 inhibitor[J]. Nutrients, 2023, 15(19): 4262.
|
28 |
Vetrano DL, Triolo F, Maggi S, et al. Fostering healthy aging: The interdependency of infections, immunity and frailty[J]. Ageing Res Rev, 2021, 69: 101351.
|
29 |
Egami S, Kawazoe H, Hashimoto H, et al. Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study[J]. J Cancer, 2021, 12(7): 2105-2112.
|
30 |
Trestini I, Sperduti I, Sposito M, et al. Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome[J]. ESMO open, 2020, 5(3): e000689.
|
31 |
Kichenadasse G, Miners JO, Mangoni AA, et al. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer[J]. JAMA Oncol, 2020, 6(4): 512-518.
|
32 |
Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab[J]. Lung Cancer, 2017, 111: 176-181.
|